Somata Genesis, Inc.

Somata Genesis, Inc. is a private biopharmaceutical company that is advancing investigation into regenerative medicine through therapeutic interventions using proprietary stem cell lines, some of which the company has developed. Somata Genesis, Inc. is manufacturing and distributing best-in-class ischemic-tolerant allogeneic stem cell products that support pre-clinical and clinical studies conducted by approved research institutions and accredited hospitals. Through proprietary processes that are in patent application, we harvest the most viable cell populations and enhance them to yield larger quantities of specific cell lines that are consistent and of the highest quality possible. This process also enables our cells to migrate, adhere, signal, engraft, differentiate and safely provide more measurable and effective outcomes compared to other stem cells on the market. Our work combines the potential of recent technological advances in genomic sequencing with regenerative therapies that will ultimately lead to better clinical outcomes. By collecting genetic information for research and clinical use it is possible to discover patterns about diseases and their causes that would otherwise remain confusing and little understood. We believe that patterns in this collected data will reveal the genetic bases of inherited diseases, infectious diseases, drug responses, degenerative and neurodegenerative diseases, cancers and many other illnesses that have personally affected nearly every person and family world-wide. The company has already translated the science from clinical trials to offer leading edge therapies for the effective treatment of a wide range of chronic diseases that have not previously been considered curable. These include MS, ALS, Parkinson’s disease and diabetes among other incurable diseases. It is possible to treat a host of other chronic autoimmune degenerative and neurodegenerative diseases with similar protocols.